Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Abbott Laboratories has agreed to pay $450 million for the right to sell Reata Pharmaceuticals’ bardoxolone outside the U.S. Bardoxolone is an oral antioxidant inflammatory modulator that turns on Nrf2, a protein that dictates the production of antioxidant and detoxification enzymes. The drug candidate has shown promise in two Phase II trials for chronic kidney disease, a condition affecting 30–40% of people with type 2 diabetes. The Abbott deal excludes some Asian markets, for which Kyowa Hakko Kirin has already licensed the drug.
This article has been sent to the following recipient: